Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...

Researchers worry that clinical vaccine trials haven't been diverse enough. Ensuring Black and ethnic minority participation in coronavirus vaccine trials is key if we want a truly effective ...

A team of scientists and physicians at Mass General Brigham has developed a single-dose oral cholera vaccine and tested it in ...

The Trump administration on Tuesday eliminated 22 mRNA vaccine development projects for COVID-19 and bird flu, a stark shift away from technology credited with bringing the United States out of the ...

Many clinical trials include a placebo group—participants who receive an inactive treatment—so researchers can compare ...

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further ...

The trial, led by a team of scientists and physicians at Mass General Brigham hospital in Boston, was investigating the ...

AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficiency diploid rabies vaccine has successfully ...

(NYSE: ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced ...

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative ...

After nearly two decades of research, India’s first dengue vaccine, DengiAll, is ready to make its mark. Designed to fight ...

November 7, 2011 — An Epstein-Barr virus (EBV) vaccine in the early phases of development may prove able to prevent infectious mononucleosis and EBV-associated cancers, without necessarily preventing ...